VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration
Stock Information for Vistagen Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.